A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung

A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 3, randomised interventional study registered as NCT05085028 by Imperial College London, with a registry enrolment figure of 1750 participants, started 2022-06-23 and due to reach its primary completion in 2027-05-31. Interventions recorded: Pembrolizumab 25 MG/ML [Keytruda]. Conditions listed: Lung Cancer, Nonsmall Cell. Primary outcome: Overall survival at 2 years. Lung eligibility wording from the registry: "* Any patient ≥18yrs who has received 6 months of pembrolizumab treatment with or without chemotherapy for advanced Non small cell lung cancer who is planned to continue immunotherapy treatment because of continued benefit". Sites: United Kingdom. United Kingdom sites listed: 37. No results are recorded here; the registry entry is the source.